Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Randi
M L
ML
Fabris
F
F
Girolami
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000209:etiology; D015477:Leukemia, Myelomonocytic, Chronic / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D010761:Phosphorus Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects; D010885:Pipobroman / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000188:drug therapy*
D000970:Antineoplastic Agents; D010761:Phosphorus Radioisotopes; D010885:Pipobroman; D002066:Busulfan; D006918:Hydroxyurea